Top Markets
#1 DogBull DogBull +108.42%
#2 MarsCoin MarsCoin +71.21%
#3 ADO Protocol ADO Protocol +52.57%
#4 Siacoin Siacoin +43.99%
#5 Ontology Gas Ontology Gas +27.21%
#6 The Bitcoin Bull The Bitcoin Bull +16.79%
#7 Useless Coin Useless Coin +16.20%
#8 Apertum Apertum +14.88%
#9 Uniswap Uniswap +12.31%
#10 UnifAI Network UnifAI Network +11.89%
Coin of the day
DogBull DogBull
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Classement en actions #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Prix de l'action
$4.74
Dernière synchronisation: 2026-08-31
Capitalisation boursière
$372.19M
Changement (1 jour)
-2.47%
Changement (1 an)
-1.04%
Pays
US
Échange Lexeo Therapeutics, Inc. Common Stock (LXEO)

Catégorie

Healthcare
Bénéfices pour Lexeo Therapeutics, Inc. Common Stock (LXEO)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Lexeo Therapeutics, Inc. Common Stock, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Lexeo Therapeutics, Inc. Common Stock de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH